Jennifer Jess

Jennifer Jess

Auto-generated profile, based on publicly available information

Jennifer Jess

Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan. 1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JJJennifer Jess
Jennifer Jess
KSKathleen M. Sorensen
Kathleen M. Sorensen
EBElissa A. Boguslawski
Elissa A. Boguslawski
MSMatthew C. Stout
Matthew C. Stout
ZMZachary B. Madaj
Zachary B. Madaj
PGPatrick J. Grohar
Patrick J. Grohar
Purpose: The importance of cellular context to the synergy of DNA damage response (DDR)-targeted agents is important for tumors with mutations in DDR pathways, but less well-established for tumors driven by oncogenic transcription factors. In this study, we exploit the widespread transcriptional dysregulation of the EWS-FLI1 transcription factor to identify an effective DDR-targeted combination therapy for Ewing sarcoma. Experimental Design: We used matrix drug screening to evaluate synergy between a DNA-PK inhibitor (M9831) or an ATR inhibitor (berzosertib) and chemotherapy. The combination of berzosertib and cisplatin was selected for broad synergy, mechanistically evaluated for Ewing sarcoma selectivity, and optimized for in vivo schedule. Results: Berzosertib combined with cisplatin demonstrates profound synergy in multiple Ewing sarcoma cell lines at clinically achievable concentrations. The synergy is due to loss of expression of the ATR downstream target CHEK1, loss of cell-cycle check-points, and mitotic catastrophe. Consistent with the goals of the project, EWS-FLI1 drives the expression of CHEK1 and five other ATR pathway members. The loss of CHEK1 expression is not due to transcriptional repression and instead caused by degradation coupled with suppression of protein translation. The profound synergy is realized in vivo with a novel optimized schedule of this combination in subsets of Ewing sarcoma models, leading to durable complete responses in 50% of animals bearing two different Ewing sarcoma xenografts. Conclusions: These data exploit EWS-FLI1 driven alterations in cell context to broaden the therapeutic window of berzosertib and cisplatin to establish a promising combination therapy and a novel in vivo schedule. See related commentary by Ohmura and Grünewald, p. 3358

15 August 2024
Verified
Other
Open access
PDF file
JJJennifer Jess
Jennifer Jess
KSKatie M. Sorensen
Katie M. Sorensen
EBElissa A. Boguslawski
Elissa A. Boguslawski
MSMatthew C. Stout
Matthew C. Stout
ZMZachary B. Madaj
Zachary B. Madaj
PGPatrick J. Grohar
Patrick J. Grohar
Supplementary Figures S1-S15 and Legends

15 August 2024
Verified
Other
Open access
JJJennifer Jess
Jennifer Jess
KSKatie M. Sorensen
Katie M. Sorensen
EBElissa A. Boguslawski
Elissa A. Boguslawski
MSMatthew C. Stout
Matthew C. Stout
ZMZachary B. Madaj
Zachary B. Madaj
PGPatrick J. Grohar
Patrick J. Grohar
Purpose:The importance of cellular context to the synergy of DNA damage response (DDR)-targeted agents is important for tumors with mutations in DDR pathways, but less well-established for tumors driven by oncogenic transcription factors. In this study, we exploit the widespread transcriptional dysregulation of the EWS-FLI1 transcription factor to identify an effective DDR-targeted combination therapy for Ewing sarcoma.Experimental Design:We used matrix drug screening to evaluate synergy between a DNA-PK inhibitor (M9831) or an ATR inhibitor (berzosertib) and chemotherapy. The combination of berzosertib and cisplatin was selected for broad synergy, mechanistically evaluated for Ewing sarcoma selectivity, and optimized for in vivo schedule.Results:Berzosertib combined with cisplatin demonstrates profound synergy in multiple Ewing sarcoma cell lines at clinically achievable concentrations. The synergy is due to loss of expression of the ATR downstream target CHEK1, loss of cell-cycle check-points, and mitotic catastrophe. Consistent with the goals of the project, EWS-FLI1 drives the expression of CHEK1 and five other ATR pathway members. The loss of CHEK1 expression is not due to transcriptional repression and instead caused by degradation coupled with suppression of protein translation. The profound synergy is realized in vivo with a novel optimized schedule of this combination in subsets of Ewing sarcoma models, leading to durable complete responses in 50% of animals bearing two different Ewing sarcoma xenografts.Conclusions:These data exploit EWS-FLI1 driven alterations in cell context to broaden the therapeutic window of berzosertib and cisplatin to establish a promising combination therapy and a novel in vivo schedule.See related commentary by Ohmura and Grünewald, p. 3358

15 August 2024
Verified
Other
Open access
JJJennifer Jess
Jennifer Jess
KSKatie M. Sorensen
Katie M. Sorensen
EBElissa A. Boguslawski
Elissa A. Boguslawski
MSMatthew C. Stout
Matthew C. Stout
ZMZachary B. Madaj
Zachary B. Madaj
PGPatrick J. Grohar
Patrick J. Grohar
Purpose:The importance of cellular context to the synergy of DNA damage response (DDR)-targeted agents is important for tumors with mutations in DDR pathways, but less well-established for tumors driven by oncogenic transcription factors. In this study, we exploit the widespread transcriptional dysregulation of the EWS-FLI1 transcription factor to identify an effective DDR-targeted combination therapy for Ewing sarcoma.Experimental Design:We used matrix drug screening to evaluate synergy between a DNA-PK inhibitor (M9831) or an ATR inhibitor (berzosertib) and chemotherapy. The combination of berzosertib and cisplatin was selected for broad synergy, mechanistically evaluated for Ewing sarcoma selectivity, and optimized for in vivo schedule.Results:Berzosertib combined with cisplatin demonstrates profound synergy in multiple Ewing sarcoma cell lines at clinically achievable concentrations. The synergy is due to loss of expression of the ATR downstream target CHEK1, loss of cell-cycle check-points, and mitotic catastrophe. Consistent with the goals of the project, EWS-FLI1 drives the expression of CHEK1 and five other ATR pathway members. The loss of CHEK1 expression is not due to transcriptional repression and instead caused by degradation coupled with suppression of protein translation. The profound synergy is realized in vivo with a novel optimized schedule of this combination in subsets of Ewing sarcoma models, leading to durable complete responses in 50% of animals bearing two different Ewing sarcoma xenografts.Conclusions:These data exploit EWS-FLI1 driven alterations in cell context to broaden the therapeutic window of berzosertib and cisplatin to establish a promising combination therapy and a novel in vivo schedule.See related commentary by Ohmura and Grünewald, p. 3358

15 August 2024
Verified
Other
Open access
JJJennifer Jess
Jennifer Jess
KSKatie M. Sorensen
Katie M. Sorensen
EBElissa A. Boguslawski
Elissa A. Boguslawski
MSMatthew C. Stout
Matthew C. Stout
ZMZachary B. Madaj
Zachary B. Madaj
PGPatrick J. Grohar
Patrick J. Grohar
Supplementary Table S2 from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma

15 August 2024
Verified
Other
Open access
JJJennifer Jess
Jennifer Jess
KSKatie M. Sorensen
Katie M. Sorensen
EBElissa A. Boguslawski
Elissa A. Boguslawski
MSMatthew C. Stout
Matthew C. Stout
ZMZachary B. Madaj
Zachary B. Madaj
PGPatrick J. Grohar
Patrick J. Grohar
Supplementary Table S2 from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma